Drug Approval | January 30, 2023
FDA approves Keytruda as adjuvant treatment for non-small cell lung cancer
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
40,000 visitors and representatives of more than 80 countries set to visit the show
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
One in two women with advanced ovarian cancer has an HRD-positive tumor
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind
Subscribe To Our Newsletter & Stay Updated
